Evidence map›Paper›PMID 41104093›Full record

ReviewFrontiers in clinical diabetes and healthcare2025

Obesity paradox in individuals with type 1 diabetes.

Hidetaka Hamasaki

Abstract readReview
In one paragraph

Review in Frontiers in clinical diabetes and healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hidetaka HamasakiJapanese Academy of Health and Practice, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The obesity paradox describes a counterintuitive phenomenon where overweight or mildly obese individuals with chronic diseases show better survival compared to those with normal weight. While this paradox has been reported in conditions such as heart failure and type 2 diabetes, its presence in type 1 diabetes (T1D) remains uncertain. This mini review summarizes current evidence from large cohort studies and a meta-analysis examining the association between body mass index (BMI) and clinical outcomes in individuals with T1D. Most findings do not support a protective effect of higher BMI; instead, both underweight and obesity are associated with increased risks of cardiovascular events and all-cause mortality. Notably, some evidence suggests that individuals with advanced diabetic nephropathy or chronic kidney disease (CKD) may show the lowest mortality at mildly elevated BMI levels. However, these observations may reflect the limitations of using BMI alone to evaluate obesity. Given that individuals with T1D often have reduced skeletal muscle mass, and that those with advanced diabetic complications or comorbidities such as CKD or cancer may develop cachexia, body composition analysis is essential. Accurate assessment of fat mass, muscle mass, bone mass, and water content is critical for understanding obesity-related risks. Future research should integrate body composition metrics to improve risk stratification in T1D.

Indexed as

body compositionbody mass indexfatmortalityobesityskeletal muscletype 1 diabetes

Identifiers

PMID41104093
PMCPMC12520960

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.